927961-18-0 Usage
Description
Lanifibranor is a novel antifibrotic clinical candidate that functions as a pan peroxisome proliferator-activated receptor (PPAR) agonist. It is designed to target and activate all three PPAR isoforms, which play a crucial role in regulating cellular differentiation, development, and metabolism. This dual-action mechanism allows Lanifibranor to address both the metabolic and fibrotic aspects of various diseases, making it a promising therapeutic agent for a range of conditions.
Uses
Used in Pharmaceutical Industry:
Lanifibranor is used as an antifibrotic agent for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and systemic sclerosis. Its pan PPAR agonist activity helps to reduce fibrosis by modulating the expression of genes involved in inflammation, lipid metabolism, and tissue repair. This makes Lanifibranor a potential treatment option for patients suffering from these debilitating conditions.
Additionally, Lanifibranor is used as a metabolic regulator for the management of metabolic disorders, such as type 2 diabetes and dyslipidemia. By activating all three PPAR isoforms, it can improve insulin sensitivity, reduce inflammation, and promote lipid homeostasis, offering a comprehensive approach to managing these metabolic conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 927961-18-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,7,9,6 and 1 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 927961-18:
(8*9)+(7*2)+(6*7)+(5*9)+(4*6)+(3*1)+(2*1)+(1*8)=210
210 % 10 = 0
So 927961-18-0 is a valid CAS Registry Number.
927961-18-0Relevant articles and documents
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
Boubia, Bena?ssa,Poupardin, Olivia,Barth, Martine,Binet, Jean,Peralba, Philippe,Mounier, Laurent,Jacquier, Elise,Gauthier, Emilie,Lepais, Valérie,Chatar, Maryline,Ferry, Stéphanie,Thourigny, Anne,Guillier, Fabrice,Llacer, Jonathan,Amaudrut, JéRome,Dodey, Pierre,Lacombe, Olivier,Masson, Philippe,Montalbetti, Christian,Wettstein, Guillaume,Luccarini, Jean-Michel,Legendre, Christiane,Junien, Jean-Louis,Broqua, Pierre
, p. 2246 - 2265 (2018/03/26)
Here, we describe the identification and synthesis of novel indole sulfonamide derivatives that activate the three peroxisome proliferator activated receptor (PPAR) isoforms. Starting with a PPARα activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile. In vitro and in vivo, compound 5 demonstrated strong activity in models that are relevant to nonalcoholic steatohepatitis (NASH) pathophysiology suggesting therapeutic potential for NASH patients.
